Zenith Epigenetics

Zenith Epigenetics Ltd. (Zenith Epigenetics) is a biotech firm in the clinical development phase that is focused on creating top-notch drugs that target bromodomain and extraterminal domain protein (BET) for treating various diseases, mainly cancer and other conditions with substantial medical needs that are not met. Our state-of-the-art epigenetic platform, consisting of pioneering biological and chemical approaches, has produced distinct, powerful, and specific BET inhibitors. Our objective is to emerge as a leading company in the field of epigenetics by translating bromodomain biology into impactful therapies.